Diabetic Neuropathy: A Guide to Pain Management

期刊论文
发表日期：

2024年7月5日

查看全文

Emily X. Zhang,
Cyrus Yazdi,
Rahib K. Islam,
Ahmed I. Anwar,
Alana Alvares-Amado,
Horace Townsend,
Kaitlyn E. Allen,
Elena Plakotaris,
Jon D. Hirsch,
Ross G. Rieger,
Varsha Allampalli,
Jamal Hasoon,
Kazi N. Islam,
Sahar Shekoohi,
Alan D. Kaye,
Christopher L. Robinson

摘要

Purpose of Review

Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.

Recent Findings

Up to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients.

Summary

Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.